Context Finding useful information from 30,000 papers is a hard task. Understanding information from all those papers takes time. With advanced AI methods, we can find and extract similar patterns from text data. This method uses advanced AI to find patterns in an unsupervised way. This will be equal to comparing all the sentences with every other sentence  in brute-force method. How this is different from other AI methods This method goes beyond sentence level co-occurrence pattern finding. As it compares each sentence with other sentences, similar or comparable patterns between the sentences are extracted rather than co-occurrence patterns by other methods. As it compares the concepts and patterns not the words, hidden but related words or phrases can be found easily. In other words, it goes beyond keyword search to bring all the related sentences in one place. This also reduces the reading requirement. Content This dataset creates similar sentences from unsupervised learning methods thus it extracts all the similar sentences which are nearly similar. It has some noise data which may not useful because it is fully unsupervised method. Data is cleaned, stopwords removed and only English language papers were considered. Final result is 4.5 million sentences. These were processed to find relevant clusters of sentences with desired similarity. One example is given below. For full text of the paper, please refer to https://www.kaggle.com/allen-institute-for-ai/CORD-19-research-challenge data. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : Antibiotics can be placed into the following relative rank order of predicted clinical efficacy for adults: 90% to 92% ch respiratory fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin), ceftriaxone, high-dose amoxicillin/clavulanate (4 g/250 mg/day), and amoxicillin/clavulanate (1.75 g/250 mg/day); 83% to 88% ch high-dose amoxicillin (4 g/day), amoxicillin (1.5 g/day), cefpodoxime proxetil, cefixime (based on H influenzae and M catarrhalis coverage), cefuroxime axetil, cefdinir, and TMP/SMX; 77% to 81% ch doxycycline, clindamycin (based on gram-positive coverage only), azithromycin, clarithromycin and erythromycin, and telithromycin; 65% to 66% ch cefaclor and loracarbef. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : Antibiotics can be placed into the following relative rank order of predicted clinical efficacy in children with ABRS: 91% to 92% ch ceftriaxone, high-dose amoxicillin/clavulanate (90 mg/6.4 mg per kg per day) and amoxicillin/clavulanate (45 mg/6.4 mg per kg per day); 82% to 87% ch highdose amoxicillin (90 mg/kg per day), amoxicillin (45 mg/kg per day), cefpodoxime proxetil, cefixime (based on H influenzae and M catarrhalis coverage only), cefuroxime axetil, cefdinir, and TMP/SMX; and 78% to 80% ch clindamycin (based on gram-positive coverage only), cefprozil, azithromycin, clarithromycin, and erythromycin; 67% to 68% ch cefaclor and loracarbef. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : Recommendations for initial therapy for adult patients with mild disease (who have not received antibiotics in the previous 4 to 6 weeks) include the following choices: amoxicillin/clavulanate (1.75 to 4 g/250 mg per day), amoxicillin (1.5 to 4 g/day), cefpodoxime proxetil, cefuroxime axetil, or cefdinir. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : Recommendations for initial therapy for children with mild disease and who have not received antibiotics in the previous 4 to 6 weeks include the following: high-dose amoxicillin/clavulanate (90 mg/6.4 mg per kg per day), amoxicillin (90 mg/kg per day), cefpodoxime proxetil, cefuroxime axetil, or cefdinir. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : The relative antimicrobial activity against isolates of S pneumoniae based on PK/PD breakpoints, 89 can be listed as: gatifloxacin / levofloxacin / moxifloxacin ([?]99%); ceftriaxone / high-dose amoxicillin (Ti clavulanate [extended-release or extra strength]) (95% to 97%); amoxicillin (Ti clavulanate) / clindamycin (90% to 92%) ; cefpodoxime proxetil /cefuroxime axetil / cefdinir /erythromycin /clarithromycin / azithromycin / telithromycin / cefprozil / TMP/SMX / cefixime (63% to 75%); loracarbef / cefaclor ([?]20%). title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : The relative antimicrobial activity against H influenzae based on PK/PD breakpoints is: gatifloxacin / moxifloxacin / ceftriaxone / cefixime / cefpodoxime proxetil / extended-release and extra strength amoxicillin/clavulanate / amoxicillin/clavulanate (95% to 100%); cefuroxime axetil / cefdinir / TMP/SMX / amoxicillin (70% to 85%); cefprozil / cefaclor / loracarbef / doxycycline / erythromycin / clarithromycin / azithromycin / telithromycin ([?]25%). title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : 89, 90 The relative antimicrobial activity against M catarrhalis is: gatifloxacin / levofloxacin / moxifloxacin / cefixime / extended-release and extra strength amoxicillin/clavulanate / telithromycin / erythromycin / clarithromycin / azithromycin (100%); doxycycline/ceftriaxone / cefpodoxime proxetil / cefdinir (78% to 96%); cefuroxime axetil (50%); cefprozil / amoxicillin/ TMP/SMX / cefaclor/loracarbef ([?]20%). title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : According to the therapeutic outcomes model, antibiotics can be placed into the following relative rank order of predicted clinical efficacy for adult patients: 90% to 92% ch respiratory quinolones (gatifloxacin, levofloxacin, moxifloxacin), ceftriaxone, amoxicillin/clavulanate (4 g/250 mg per day), and amoxicillin/clavulanate (1.75 g/250 mg per day); 83% to 88% ch high-dose amoxicillin (4 g/day), amoxicillin (1.5 g/day), cefpodoxime proxetil, cefixime (based on H influenzae and M catarrhalis coverage only), cefuroxime axetil, cefdinir, and TMP/SMX; 77% to 81% ch doxycycline, clindamycin (based on gram-positive coverage only), cefprozil , azithromycin, clarithromycin, erythromycin, and telithromycin; 65% to 66% ch cefaclor and loracarbef. title : Antimicrobial treatment guidelines for acute bacterial rhinosinusitis Executive Summary SINUS AND ALLERGY HEALTH PARTNERSHIP* paper id : 32d8d8a2e5e0a499c98a53c9f71a22469752247e line : According to the Poole therapeutic outcomes model, antibiotics can be placed into the following relative rank order of predicted clinical efficacy in children: 91% to 92% ch ceftriaxone, high-dose amoxicillin/clavulanate (90 mg/6.4 mg per kg per day), and amoxicillin/clavulanate (45 mg/6.4 mg per kg per day); 82% to 87% ch high-dose amoxicillin (90 mg/kg per day), amoxicillin (45 mg/kg per day), cefpodoxime proxetil, cefixime (based on H influenzae and M catarrhalis coverage only), cefuroxime axetil, cefdinir, and TMP/SMX; 78% to 80% ch clindamycin (based on gram-positive coverage only), cefprozil, azithromycin, clarithro- 89, 90 (*The activity of telithromycin against S pneumoniae, H influenzae, and M catarrhalis depends on its PK/PD profile, which is un